Industry
Biotechnology
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Loading...
Open
5.12
Mkt cap
185M
Volume
994K
High
5.40
P/E Ratio
-2.04
52-wk high
10.48
Low
5.01
Div yield
N/A
52-wk low
1.59
Portfolio Pulse from
December 14, 2024 | 1:45 pm
Portfolio Pulse from
December 10, 2024 | 10:15 pm
Portfolio Pulse from
December 10, 2024 | 9:15 pm
Portfolio Pulse from
November 15, 2024 | 11:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 21, 2024 | 12:01 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.